Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

387.50USD
29 Mar 2017
Change (% chg)

$4.95 (+1.29%)
Prev Close
$382.55
Open
$382.46
Day's High
$387.50
Day's Low
$382.46
Volume
14,283
Avg. Vol
308,217
52-wk High
$452.83
52-wk Low
$325.62

Latest Key Developments (Source: Significant Developments)

U.S. list price for Sanofi, Regeneron's Dupixent $37,000
Tuesday, 28 Mar 2017 11:47am EDT 

Sanofi : Says U.S. list price of newly approved Dupixent atopic dermatitis drug $37,000 per patient per yearFurther company coverage: [SASY.PA] (Reporting by Ben Hirschler) ((uk.online@reuters.com;)).  Full Article

U.S. FDA says approves new eczema drug Dupixent
Tuesday, 28 Mar 2017 11:47am EDT 

U.S. FDA: FDA approves new eczema drug Dupixent . FDA granted the application for Dupixent priority review and breakthrough therapy designation .FDA granted the approval of Dupixent to Regeneron Pharmaceuticals Inc.  Full Article

Regeneron and Sanofi announce FDA approval of Dupixent
Tuesday, 28 Mar 2017 11:40am EDT 

Sanofi SA : Regeneron and Sanofi announce FDA approval of Dupixent® (Dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis . Dupixent is expected to be available to patients and providers in U.S. later this week .Regeneron and Sanofi Genzyme, specialty care global business unit of Sanofi, will market Dupixent in United States.  Full Article

UK regulator gives positive opinion on Sanofi/Regeneron's dupilumab product
Tuesday, 14 Mar 2017 04:30am EDT 

Sanofi : Sanofi says UK's Medicines & Healthcare Products Regulatory Agency (MHRA) has granted dupilumab, a product which treats for atopic dermatitis (AD), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). . The decision means that eligible adults with severe atopic dermatitis can access dupilumab before the drug is granted marketing authorisation in the UK, Sanofi adds in statement .Dupilumab is currently under joint development with Regeneron and Sanofi and its safety and efficacy have not been fully evaluated by any regulatory body. The formal EU regulatory application for dupilumab is currently under review by the European Medicines Agency (EMA)..  Full Article

Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions
Tuesday, 7 Mar 2017 08:00am EST 

Regeneron Pharmaceuticals Inc : Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions .Regeneron Pharmaceuticals Inc says effect of praluent on cardiovascular (CV) morbidity and mortality has not yet been determined.  Full Article

Adverum says Regeneron Pharma elects to extend research term of deal
Wednesday, 1 Mar 2017 04:59pm EST 

Adverum Biotechnologies Inc : Adverum Biotechnologies-on Feb 23, Regeneron Pharma notified Adverum Biotechnologies of election to extend research term of collaboration, licensing deal .Adverum Biotechnologies - Regeneron Pharma elected to extend research term of deal for additional three years, through May 1, 2020.  Full Article

Regeneron posts Q4 adj. profit $3.04/shr
Thursday, 9 Feb 2017 06:32am EST 

Regeneron Pharmaceuticals Inc : Regeneron reports fourth quarter and full year 2016 financial and operating results . Regeneron Pharmaceuticals Inc - Q4 2016 eylea global net sales increased 17 pct to $1.35 billion versus Q4 2015 . Regeneron Pharmaceuticals Inc - in Q4 of 2016, global net sales of praluent were $41 million, compared to $7 million in Q4 of 2015 . Says net product sales were $863 million in Q4, compared to $750 million . Regeneron Pharmaceuticals Inc - total revenues increased by 12 pct to $1.227 billion in Q4 of 2016 . Regeneron Pharmaceuticals Inc - sees 2017 Sanofi reimbursement of Regeneron commercialization-related expenses of $400 million - $450 million . Regeneron Pharmaceuticals Inc qtrly non-GAAP net income per share $3.04 . Qtrly GAAP net income per share $2.19 . Q4 earnings per share view $3.03, revenue view $1.30 billion -- Thomson Reuters I/B/E/S . Regeneron Pharmaceuticals Inc - sees single digit percentage growth over 2016 for eylea U.S. net product sales in 2017 . Regeneron Pharmaceuticals Inc - "also studying dupixent in patients with nasal polyps and pediatric patients with asthma or atopic dermatitis" . Regeneron - dupixent may have potential to help additional patients with serious allergic diseases, Phase 3 data in adult asthma patients expected later this year . Regeneron Pharmaceuticals Inc - pre-approval inspection for dupixent has been scheduled for Q1 of 2017.  Full Article

Sanofi buys 87,298 shares of Regeneron's common stock on Jan 11
Friday, 13 Jan 2017 04:28pm EST 

:Sanofi reports open market purchase of 87,298 shares of Regeneron Pharmaceuticals Inc's common stock on Jan 11 - SEC filing.  Full Article

Regeneron says Sanofi plant used to fill drugs now deemed acceptable
Monday, 9 Jan 2017 07:26pm EST 

Regeneron Pharmaceuticals Inc : Regeneron CEO says Sanofi plant that will fill atopic dermatitis drug awaiting U.S. approval decision deemed acceptable . Regeneron CEO predicts PBMs will pay for Dupixent atopic dermatitis drug once approved . Regeneron ceo says expects to file for U.S. approval of dupilumab for asthma in Q4 . Regeneron sees 2017 reimbursement of commercialization expenses from Sanofi of $400 million to $450 million .Regeneron sees 2017 capital expenditures $375 million to $450 million.  Full Article

Regeneron says Sanofi plant used to fill drugs now deemed acceptable
Monday, 9 Jan 2017 06:49pm EST 

Regeneron Pharmaceuticals Inc : Regeneron CEO says Sanofi plant that will fill atopic dermatitis drug awaiting U.S. approval decision deemed acceptable . Regeneron CEO predicts PBMs will pay for Dupixent atopic dermatitis drug once approved . Regeneron ceo says expects to file for U.S. approval of dupilumab for asthma in Q4 . Regeneron sees 2017 reimbursement of commercialization expenses from Sanofi of $400 million to $450 million .Regeneron sees 2017 capital expenditures $375 million to $450 million.  Full Article

More From Around the Web

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies.